Russia trying to buy up praise for Sputnik-V vaccine
This post has already been read 167 times!
Russia has dove into colossal spending to get corrupt journalists and experts, who have lost their credibility, to spread a good word about their corona drug.
It is fundamentally important for Russian propaganda to make an impression that their Sputnik V outplays international rivals and enjoys mad global demand.
In fact, the campaign promoting the drug that hasn’t even completed clinical trials, at the same time raising concerns over dangerous side effects and ambiguous stability and efficacy, chose to snub any scientific data or fantastic results (there are none), opting for bribery of media pundits and aggressive spins. In some cases, however, zealous efforts of Russian propaganda managers lead to embarrassing confusion, as was the case with The New York Times.
In early January, the newspaper’s Moscow-based correspondent, Andrew Kramer, got himself a Russian jab, claiming he intends to dispel mistrust of the Russian vaccine, at the same time praising Moscow’s unique experience in vaccine development that stems from Soviet times. Naturally, Russian media overwhelmingly applauded the move: “Hey, look, here’s an American guy, who’s not afraid to get inoculated with the Russian drug. Breaking news!”
Meanwhile, less than a month into the release of Kramer’s report, the same newspaper, The New York Times, publishes a piece entitled “Russian campaign promotes home-grown vaccine and cuts competitors”, exposing Russia’s efforts to compromise foreign-made vaccines, spreading fake news and manipulating data. The campaigns mainly target audiences in Latin America, especially in Mexico and Argentina.